SOURCE: Frost & Sullivan

March 16, 2011 01:30 ET

Rising Burden of Infectious and Non-Communicable Diseases Creates Significant Growth Potential for Pharmaceutical Companies in SADC Countries, Finds Frost & Sullivan

CAPE TOWN, SOUTH AFRICA--(Marketwire - March 16, 2011) -  Infectious diseases in the Southern African Development Community (SADC) countries still present the biggest burden of disease. However, urbanisation and westernised lifestyles have led to the rise of non-communicable diseases, especially in countries like Mauritius, where they account for a majority of the country's disease burden. Increased access to high-quality treatments is essential in alleviating the heavy burden of non-communicable diseases within the country.

New analysis from Frost & Sullivan (, SADC Pharmaceutical Industry, finds that the industry in Mauritius, Malawi and Zambia, generated revenues of $228.7 million in 2009 and estimates this to reach $439.6 million in 2016. The therapeutic segments included in this research are anti-infectives, oncology, diabetes and cardiovascular.

 "The rapidly increasing number of diseases in SADC is the biggest driver of growth in the region," notes Frost & Sullivan Healthcare Research Analyst Jolize Gerber. "Infectious diseases, including AIDS, malaria and TB still present the largest opportunity for the provision of pharmaceuticals in the region, especially in Zambia and Malawi."

The high burden of infectious diseases will spur strong investments in anti-infective treatments. At the same time, the large number of non-communicable or lifestyle diseases like hypertension and diabetes will also drive market development.

"Rapid industrialisation and the consequent change to a more westernised lifestyle have contributed to the high prevalence of non-communicable disease risk factors in Mauritius," remarks Gerber. "These include obesity (10.3%), abusive alcohol consumption (19.1%) and tobacco consumption (35.9% among males)."

Non-communicable diseases such as cardiovascular disease and diabetes are the most common diseases in both hospital and non-hospital settings. They account for over 80.0 per cent of Mauritius's disease burden. Mauritius ranks among the countries with the highest prevalence of diabetes mellitus and hypertension in Africa.

Limited buying power, an acute shortage of skilled healthcare workers and poor distribution infrastructure to rural areas still limit the access to essential treatments. Furthermore, the proliferation of low-quality and counterfeit products remains a major challenge for reputable pharmaceutical suppliers, as these products pose direct competition to high-quality pharmaceuticals.

"Increased access to high quality treatments is essential in alleviating the high burden of non-communicable diseases," advises Gerber. "Recently, the Ministry of Health in Mauritius has devoted more attention to the threat of non-communicable disease, realising that the high disease burden not only impacts healthcare services but also has a profound social and economic impact on the country."

SADC Pharmaceutical Industry is part of the Pharmaceuticals & Biotechnology Growth Partnership Services programme, which also includes research in the following markets: Healthcare industry in Namibia, Pharmaceutical industry in Botswana, Healthcare regulatory environment in SADC and Healthcare industry in Ghana. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

If you are interested in more information n this study, please send an e-mail to Christie Cronje, Corporate Communications, at, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit

SADC Pharmaceutical Industry

Contact Information